Surgery Partners amended its merger agreement, providing $25.00 per share in cash plus a potential ticking fee. Third-quarter revenue fell 0.8% to $815.3 million and Adjusted EBITDA declined 2.7% to $132.7 million.
On the terms and subject to the conditions of the Amended Merger Agreement, at the Effective Time of the Merger, each issued and outstanding share of Company common stock as of immediately prior to the Effective Time (other than certain excluded shares, including the Rollover Shares) will be converted into the Per Share Consideration of $25.00 in cash, without interest.The Merger Agreement Amendment further provides in the event the requisite Company stockholder approval has been obtained but the Merger has not occurred by March 1, 2027, the Company’s stockholders (other than certain excluded shares, including shares held by rollover stockholders) will receive additional monthly Ticking Fee cash payments, which payments will be paid in equal monthly installments in arrears at a rate equal to 10% per annum on the $25.00 per share merger consideration.Total revenues for the third quarter of 2026 decreased (0.8)% to $815.3 million from $821.5 million in the third quarter of 2025.For the third quarter of 2026, Adjusted EBITDA decreased 2.7% to $132.7 million compared to $136.4 million for the same period in 2025.Open the document at this passage
Board reaffirmed Surgery Partners’ amended HealthSpan Partners deal, valued at up to approximately $6.0 billion, after rejecting a competing proposal over closing and regulatory risks. The transaction is expected to close in the first quarter of 2027.
5 source passages
HealthSpan Partners will now acquire Surgery Partners in an all-cash transaction valued at an enterprise value of up to approximately $6.0 billion.Our Board of Directors reaffirms its recommendation in support of the acquisition by HealthSpan Partners and the HealthSpan Partners merger agreement, as amended, remains in full effect.Notably, the third party proposal would be expected to take materially longer to close than the amended HealthSpan proposal, or may not close, which reduces the value of the proposed consideration to our stockholders.Additionally, our Board of Directors and the Special Committee considered the regulatory risk and complexity of a deal with the third party compared with HealthSpan Partners.The transaction is still expected to close in the first quarter of 2027, subject to the approval of Surgery Partners stockholders, the receipt of regulatory approvals and satisfaction of other customary closing conditions.Open the document at this passage
Surgery Partners amended its merger agreement after an unsolicited competing proposal, with HealthSpan Partners acquiring it in an all-cash transaction valued at an enterprise value of up to approximately $6.0 billion; closing remains expected in the first quarter of 2027.
3 source passages
The amendment follows Surgery Partners’ receipt of an unsolicited competing proposal from a third party.HealthSpan Partners will now acquire Surgery Partners in an all-cash transaction valued at an enterprise value of up to approximately $6.0 billion.The transaction is still expected to close in the first quarter of 2027, subject to the approval of Surgery Partners stockholders, the receipt of regulatory approvals and satisfaction of other customary closing conditions.Open the document at this passage
Surgery Partners amended its merger agreement with HealthSpan Partners, increasing cash consideration to $25.00 per share and enterprise value to up to approximately $6.0 billion. Third-quarter revenue was $815.3 million, down (0.8)%, while Adjusted EBITDA was $132.7 million.
Financial results3 source passages
On November 9, 2026, Surgery Partners announced an amendment to its previously announced merger agreement with HealthSpan Partners, following Surgery Partners’ receipt of an unsolicited competing proposal from a third party. The amendment increases the merger consideration to $25.00 per share in cash, representing an enterprise value of up to approximately $6.0 billion.Revenues for the third quarter of 2026 decreased (0.8)% to $815.3 million compared to $821.5 million for the third quarter of 2025.For the third quarter of 2026, the Company’s Adjusted EBITDA was $132.7 million, compared to $136.4 million for the same period in 2025.Open the document at this passage
Surgery Partners amended its HealthSpan Partners merger agreement to increase cash consideration to $25.00 per share. If closing occurs after March 1, 2027, holders may receive additional monthly payments at 10% per annum, capped at $1.61 per share.
Read from the first part of this long document3 source passages
Surgery Partners and HealthSpan Partners Announce Amended Merger Agreement, Following Receipt of Unsolicited ProposalIf the transaction closes after March 1, 2027, up to an additional $1.61 per share in cash in Ticking Fees depending on the closing dateThe amendment to the HealthSpan Partners merger agreement increases the merger consideration to $25.00 per share in cash and further provides that the Company’s stockholders (other than affiliates of Bain Capital Private Equity (“Bain Capital”)) will receive additional monthly cash payments (the “Ticking Fee”) in the event the requisite Company stockholder approval has been obtained but the merger between HealthSpan Partners and Surgery Partners has not occurred by March 1, 2027, which payments will be paid in equal monthly installments in arrears at a rate equal to 10% per annum on the $25.00 per share merger consideration, among other updates (the “Amended HealthSpan Proposal”).Open the document at this passage
Surgery Partners agreed to be acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, in an all-cash transaction valued at approximately $5.7 billion; closing is expected in the first quarter of 2027.
Surgery Partners signed an agreement with HealthSpan Partners to acquire its business, expected to close in the first quarter of 2027 pending proxy, regulatory and shareholder approval; Bain Capital agreed to support the transaction.
Surgery Partners agreed to be acquired by HealthSpan Partners in an all-cash transaction valued at approximately $5.7 billion; shareholders other than Bain Capital Private Equity affiliates will receive $23.50 per share, a 64% premium. Closing is expected in the first quarter of 2027.
On October 23, 2026, Surgery Partners, Inc. agreed to be acquired by Spyglass Topco, LLC for $23.50 in cash per eligible outstanding share; rollover, treasury, subsidiary-owned and appraisal shares are excluded. Completion requires stockholder approval and other closing conditions.
Surgery Partners, Inc. entered a merger agreement on October 23, 2026 under which Spyglass Topco, LLC would acquire it for $23.50 per share, subject to stockholder and regulatory approvals.
